VERICIGUAT
Approved for formulary October 2023 with criteria for use for symptomatic patients on optimized GDMT or unable to tolerate GDMT.
Approved for formulary October 2023 with criteria for use for symptomatic patients on optimized GDMT or unable to tolerate GDMT.